TRABI Stock View

Transgene Biotek Ltd

TRABI Stock View

(BSE)

Trade

0.29 | 3.72

Market Cap ₹( Cr.)
612.98

Proj. P/E (x)

Proj. P/BV (x)

Proj. ROE (%)

Proj EV / EBITDA (x)
--

Proj. Revenue ( Cr.)

Last Updated On.
26-Nov-2023

 

Copy Link

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. It also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data